Core Points - Theon International Plc is launching a rights offering to raise approximately €150 million through the issuance of 8,624,645 new ordinary shares at a subscription price of €17.40 per share, which represents a discount of 30.8% to the theoretical ex-rights price [3][4][10] - The majority shareholders, Venetus Limited and CHRE Investments Limited, have committed to subscribe for approximately €107 million of new shares, representing about 71.0% of the offering [5][6] - The proceeds from the rights offering are intended to partially finance the acquisition of a 9.8% stake in Exosens SA for €268.7 million, positioning Theon as the second-largest shareholder in Exosens [6][8][7] Offering Details - The rights offering will allow existing shareholders to receive 1 right per ordinary share held as of the record date, with 8 rights required to subscribe for 1 new share [4][9] - The subscription period will run from December 2, 2025, to December 15, 2025, with rights trading occurring from December 2 to December 11, 2025 [12][13] - Any unsubscribed shares will be offered to eligible institutional investors through private placements [15] Financial Context - The subscription price of €17.40 per share is based on a closing price of €26.10 per ordinary share, indicating a significant discount [10] - The expected net proceeds from the offering are approximately €146 million, which will be utilized for the Exosens acquisition [8] Company Background - Theon Group specializes in developing and manufacturing advanced night vision and thermal imaging systems for defense and security applications, with a global presence [34] - The company has been listed on Euronext Amsterdam since February 2024 and has over 240,000 systems in service across 71 countries, including 26 NATO member countries [34]

Share capital increase reserved for employees “Elis for All 2025” Saint-Cloud, 13 November 2025 The subscription period for the share capital increase reserved for Elis employees ended on 2 October 2025. 5.8% of employees in 20 countries chose to participate, either directly or via the Elis Group employee shareholding fund, in this operation, for a total subscription of nearly 15 million euros. Implemented by the Elis Supervisory Board on December 17, 2024 and by the Management Board on July 31, 2025, on th ...

Core Points - The EfTEN Real Estate Fund AS shareholders authorized the Supervisory Board to increase the fund's share capital through public and/or private offerings, excluding pre-emptive subscription rights of existing shareholders for one year [1] - The fund plans to conduct a directed share issue to raise a total of 1.6 million euros, primarily from Lithuania, with a share price set at 19.11 euros per share based on the 60-day average closing price [2] - A total of 84,506 new shares will be issued at a nominal value of 10 euros per share, resulting in a new share capital of 115,248,460 euros, with proceeds intended to finance further investment activities [3]

Group 1 - The extraordinary general meeting of Havila Kystruten AS resolved to conduct a share consolidation in the ratio of 50:1 [1] - A share capital increase was approved to facilitate the share consolidation due to the current number of shares not being divisible by 50 [1] - Havila Holding AS, associated with primary insiders, subscribed for 41 shares in the share capital increase [2]

Core Points - The Board of Directors of Havila Kystruten AS has announced an extraordinary general meeting scheduled for November 7, 2025, at 10:00 CET [1] - The agenda includes the election of independent board members, a reverse share split in the ratio of 50:1, and a share capital increase to facilitate the share consolidation [2] - Shareholders with non-divisible shares will have their holdings rounded down, and fractional shares will be sold with proceeds donated to charity [3] - The meeting will be conducted digitally with electronic voting options available [4] Agenda Items - Election of Board members to ensure independence for potential refinancing [2] - Implementation of a reverse share split at a ratio of 50:1 [2] - Proposal for a share capital increase to support the share consolidation [2] - Authorization for the Board to set key dates related to the share consolidation and change of ISIN [2] Shareholder Information - Shareholders must hold a number of shares divisible by 50 to avoid rounding down [3] - Fractional shares will not be issued, and no compensation will be provided for rounding [3] - Proceeds from the sale of consolidated fractional shares will be donated to a charitable cause [3] Meeting Logistics - The extraordinary general meeting will be held as a digital meeting with electronic voting via Lumi [4] - Advance voting and proxy authorizations are permitted [4] - Relevant documents and meeting notice are available on the company's website [4]

Core Points - The Company announced the exercise of 19,470,726 Warrants, resulting in the subscription for the same number of new shares at an exercise price of NOK 1.00 each [1] - The Board of Directors has approved the allocation of new shares and resolved to increase the Company's share capital accordingly [2] - Following the registration of the share capital increase, the Company's total share capital will amount to NOK 429,142,639.50, divided into 858,285,279 shares with a nominal value of NOK 0.50 each [3] Company Overview - Ensurge Micropower is focused on developing ultrathin, flexible, reliable, and fundamentally safe solid-state lithium microbattery technology [3] - The Company operates with a team of forty specialists based in Silicon Valley, emphasizing innovation in microbattery technology suitable for various applications, including wearables and IoT devices [4] - Ensurge's manufacturing facility utilizes patented process technology and aims to scale production through partnerships with specialized industrial manufacturers [5] - The Company is listed on the Norwegian stock exchange and is supported by reputable financial investors, indicating a strong strategic investment and collaboration [6]

Core Points - Zealand Pharma A/S announced the total number of shares and voting rights as of September 30, 2025, following a share capital increase due to the exercise of employee warrants [1][2] - The total number of shares is 71,364,728, with a corresponding share capital of DKK 71,364,728 and the same number of voting rights [3] Company Overview - Zealand Pharma A/S is a biotechnology company focused on the discovery and development of innovative peptide-based medicines, with over 10 drug candidates in clinical development, including two that have reached the market and three in late-stage development [3] - The company was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States [4]

Group 1 - The company Kaldvik AS has resolved to settle a receivable of NOK 43,594,165 related to the acquisition of Mossi ehf. by issuing 1,579,498 new shares [1][2] - The new shares will be issued to Heimstø AS, which is associated with a primary insider of Kaldvik AS [2] - Following the share capital increase, the company's total share capital will amount to NOK 16,826,833.50, divided into 168,268,335 shares, each with a nominal value of NOK 0.10 [3] Group 2 - The company will register the new share capital increase with the Norwegian Register of Business Enterprises and will announce the completion of this registration [3] - This information is subject to the disclosure requirements of Regulation EU 596/2014 (MAR) and the Norwegian Securities Trading Act [4]

Group 1 - The Company, Grigeo Group AB, has announced that it received notifications of transactions conducted by persons discharging managerial responsibilities [1] - These transactions involve the acquisition of shares in the Company, completing the implementation of a resolution from the Annual General Meeting of Shareholders held on April 28, 2025, to increase the Company's share capital and approve revised Articles of Association [2] - Under this resolution, shares have been granted to employees of the Company and its subsidiaries free of charge through the issuance of new shares, which were fully paid from a reserve established for this purpose [3]

Core Points - The Board of EPSO-G has convened an Extraordinary General Meeting to discuss significant investment decisions [1] - EPSO-G plans to invest EUR 18,643,560 in its subsidiary UAB EPSO-G Invest by increasing its authorized capital and shares [2] - The meeting agenda includes the approval of the decision to increase shares in UAB EPSO-G Invest and the essential terms of the share subscription agreement [3] Company Structure - EPSO-G is a holding company with six direct subsidiaries: Amber Grid, Baltpool, Energy Cells, EPSO-G Invest, Litgrid, and Tetas [4] - EPSO-G and its subsidiaries also hold shares in GET Baltic, Baltic RCC OÜ, and TSO Holding AS [4] - The Ministry of Energy of the Republic of Lithuania exercises the rights and obligations of the sole shareholder of EPSO-G [4]